|
ression.Common:Anaemia.Very rare:Irreversible bone marrow failure.Although bone marrow suppression frequently occurs, it is usually reversible if Leukeran is withdrawn early enough.Immune system disorders Uncommon:Rash.Rare:Allergic reactions such as urticaria and angioneurotic oedema following initial or subsequent dosing. Stevens-Johnson syndrome and toxic epidermal necrolysis.(See Skin and subcutaneous tissue disorders)On rare occasions skin rash has been reported to progress to serious conditions including Stevens-Johnson Syndrome and toxic epidermal necrolysis.Nervous system disorders Common:Seizures in children with nephrotic syndrome.Rare:Seizures# , focal and/or generalised in children and adults receiving therapeutic daily doses or high pulse dosing regimens of chlorambucil.Very rare:Movement disorders including tremor, twitching and myoclonia in the absence of convulsions. Peripheral neuropathy.#Patients with a history of seizure disorder may be particularly susceptible.Respiratory, thoracic and mediastinal disordersVery rare:Interstitial pulmonary fibrosis, interstitial pneumonia.Severe interstitial pulmonary fibrosis has occasionally been reported in patients with chronic lymphocytic leukaemia on long-term Leukeran therapy. However, this may be reversible on withdrawal of Leukeran.Gastrointestinal disorders Common:Gastro-intestinal disturbances such as nausea and vomiting, diarrhoea and oral ulceration.Hepatobiliary disorders Rare:Hepatoxicity, jaundice.Skin and subcutaneous tissue disorders Uncommon:Rash.Rare:Allergic reactions such as urticaria and angioneurotic oedema following initial or subsequent dosing. Stevens-Johnson syndrome and toxic epidermal necrolysis.(See Immune system disorders)On rare occasions skin rash has been reported to progress to serious conditions including Stevens-Johnson syndrome and toxic epidermal necrolysis.Renal and urinary disorders Very rare:Sterile cystitis.General disorders and administration site conditions >Rare:Drug fever.
Manufacturer
GlaxoSmithKline(GSK)
Drug Availability
(POM)
Updated
19 May 2009
|
